


FIG. 1A






FIG. 2




FIG. 3




FIG. 4

IV dosing	Clearance	Cmin,last (ng/mL)	Cmax,last (ng/mL)	Cavg,last (ng/mL)	% of subjects above 32 µg/mL at Cmin,last
1 dose of 1400mg IV	Nominal	186,000	420,000	167,000	99.4

FIG. 5

SC dosing	Clearance	Cmin,ss (ng/mL)	Cmax,ss (ng/mL)	Cavg,ss (ng/mL)	% of subjects above 3.2 µg/mL at Cmin,last
12 doses of 450mg SC QW	Nominal	6,570	10,800	9,110	97.1

FIG. 6

Albuminuria categories					
A1		A2		A3	
Normal to mildly increased		Moderately increased		Severely increased	
<30 mg/g <3 mg/mmol		30-299 mg/g 3-29 mg/mmol		≥300 mg/g ≥30 mg/mmol	
CKD Stages	G1	Normal or high	≥90	1	2
	G2	Mildly decreased	60-90	1	2
	G3a	Mildly to moderately decreased	45-59	2	3
	G3b	Moderately to severely decreased	30-44	3	3
	G4	Severely decreased	15-29	3	4
	G5	Kidney failure	<15	4	4
Key to Figure: Numbers/Colors: Represents the risk for progression, morbidity and mortality by number/ color from best to worst. 0- Green: Low Risk (if no other markers of kidney disease, no CKD) 1- Yellow: Moderately Increased Risk 2- Orange: High Risk 3- Red: Very High Risk 4- Deep Red: Highest Risk					

FIG. 7A




FIG. 7B

	COMPOUND B Treated										Part 2 - MAD Summary	
	Part 1 - SAD Summary										Summary	
	Cohort 1 (N = 4)	Cohort 2 (N = 4)	Cohort 3 (N = 4)	Cohort 4a (N = 4)	Cohort 4b (N = 4)	Cohort 6a (N = 4)	Cohort 6b (N = 4)	Cohort 8 (N = 4)	COMP.B (N = 32)	Placebo (N = 17)	COMP.B (N = 4)	Placebo (N = 3)
Age (years) ^a												
Mean (SD)	31.8 (13.8)	32.0 (12.9)	27.3 (9.9)	37.3 (14.2)	35.8 (18.2)	28.5 (7.6)	36.0 (9.7)	36.0 (11.0)	33.1 (11.6)	33.2 (11.0)	44.0 (14.5)	32.3 (19.6)
Min, max	21, 52	23, 51	18, 41	27, 58	18, 56	21, 38	28, 50	24, 48	18, 58	18, 59	29, 60	21, 55
Sex, n (%)												
Male	1 (25.0)	0	0	1 (25.0)	1 (25.0)	3 (75.0)	0	2 (50.0)	8 (25.0)	7 (41.2)	2 (50.0)	0
Female	3 (75.0)	4 (100)	4 (100)	3 (75.0)	3 (75.0)	1 (25.0)	4 (100)	2 (50.0)	24 (75.0)	10 (58.8)	2 (50.0)	3 (100)
Race, n (%)												
Asian	0	0	0	1 (25.0)	1 (25.0)	0	0	0	2 (6.3)	1 (5.9)		
White	4 (100)	4 (100)	4 (100)	3 (75.0)	3 (75.0)	4 (100)	4 (100)	4 (100)	30 (93.8)	16 (94.1)	4 (100)	3 (100)
Weight (kg) ^b												
Mean (SD)	75.80 (25.09)	60.30 (10.10)	59.88 (7.39)	65.38 (10.58)	78.28 (13.61)	67.43 (18.55)	68.48 (8.85)	74.65 (20.15)	68.56 (15.03)	72.20 (15.53)	78.10 (7.35)	67.20 (7.55)
Min, max	57.2, 112.1	50.9, 73.1	51.1, 69.0	55.2, 79.8	61.5, 90.6	46.1, 90.0	59.0, 77.9	52.7, 92.4	46.1, 112.0	51.0, 99.7	67.3, 83.2	59.5, 74.6
BMI (kg/m ²) ^c												
Mean (SD)	26.23 (5.91)	22.60 (4.77)	21.53 (1.88)	24.25 (2.78)	25.58 (4.19)	23.13 (4.18)	24.33 (5.22)	24.65 (4.28)	23.95 (3.95)	23.29 (3.26)	24.93 (2.16)	22.83 (2.27)
Min, max	19.8, 32.1	17.4, 26.9	18.8, 23.0	20.3, 26.7	21.5, 31.3	18.0, 28.1	19.7, 31.2	18.7, 28.8	17.8, 32.0	18.8, 28.9	21.7, 26.3	21.1, 25.4

FIG. 7C

Number of Participants with a TEAE Provided by Preferred Term	Part 1 - SAD								Part 2 - MAD		
	Cohort 1 (N = 6) n (%)	Cohort 2 (N = 6) n (%)	Cohort 3 (N = 6) n (%)	Cohort 4a (N = 6) n (%)	Cohort 4b (N = 6) n (%)	Cohort 6a (N = 6) n (%)	Cohort 6b (N = 6) n (%)	Cohort 8 (N = 6) n (%)	Total (N = 49) n (%)	Cohort 1 (N = 7) n (%)	Total (N = 7) n (%)
Total number of participants with any TEAE	4 (66.7)	3 (50.0)	4 (66.7)	4 (66.7)	2 (33.3)	7 (100.0)	4 (66.7)	5 (83.3)	33 (67.3)	7 (100.0)	7 (100.0)
Headache	0	2 (33.3)	4 (66.7)	2 (33.3)	1 (16.7)	3 (42.9)	1 (16.7)	0	13 (26.5)	1 (14.3)	1 (14.3)
Nasopharyngitis	0	0	0	3 (50.0)	1 (16.7)	1 (14.3)	2 (33.3)	1 (16.7)	8 (16.3)	4 (57.1)	4 (57.1)
Injection site reaction	0	0	0	0	2 (33.3)	0	3 (50.0)	0	5 (10.2)	4 (57.1)	4 (57.1)
Blood creatine phosphokinase increased	1 (16.7)	0	0	0	0	1 (14.3)	0	0	2 (4.1)	0	0
Cough	0	0	0	0	0	2 (28.6)	0	0	2 (4.1)	2 (28.6)	2 (28.6)
COVID-19	0	0	0	0	1 (16.7)	0	0	2 (33.3)	3 (6.1)	1 (14.3)	1 (14.3)
Hot flush	0	0	0	0	0	0	0	2 (33.3)	2 (4.1)	0	0
Back pain	0	0	0	1 (16.7)	0	0	0	0	1 (2.0)	1 (14.3)	1 (14.3)
Panic attack	0	0	0	1 (16.7)	0	1 (14.3)	0	0	2 (4.1)	0	0
Dysmenorrhoea	0	1 (16.7)	0	0	0	0	0	1 (16.7)	2 (4.1)	0	0
Rhinitis	0	0	0	0	0	1 (14.3)	0	0	1 (2.0)	1 (14.3)	1 (14.3)

FIG. 7D




FIG. 7E




FIG. 7F




FIG. 7G




FIG. 7H




FIG. 7I




FIG. 7J




FIG. 7K

